DelveInsight’s “Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cancer Anorexia Overview
Cancer is the second leading cause of death worldwide. Toward the end of life, individuals with cancer experience a substantial symptom burden. The top three common symptoms in patients with cancer at the end of life are fatigue, pain, and anorexia (appetite loss). Anorexia is the lack or loss of appetite or desire to eat leading to reduced intake; associated with metabolic derangements, including the release of proinflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha produced by the immune system and tumor cells. It is the most common cause of decreased nutrient intake that triggers malnutrition and muscle wasting.
Cancer Anorexia Market Report
The cancer anorexia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM cancer anorexia market size from 2018 to 2030. The report also covers current cancer anorexia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/cancer-anorexia-market
Cancer Anorexia Epidemiology Insights
Several secondary sources suggest that patients with cancer are at particularly high risk for malnutrition (anorexia) because both the disease and its treatments threaten their nutritional status. It is estimated that the deaths of 10-20% of patients with cancer can be attributed to malnutrition rather than to the malignancy itself.
Some of the key highlights of the Cancer Anorexia market report-
Over half of the 644 ambulatory oncology patients who were surveyed suffered from a failing appetite, decreased oral intake, or weight loss of greater than 5% pre-morbid weight. These prevalence rates may be even higher if one surveys non-ambulatory patients with late-stage disease.
The symptomatic prevalence of anorexia in advanced cancer patients was 30-90% among 9113 patients included in the study. The study also suggested that the number of cancer patients in Europe experiencing anorexia each year can be approximately 510,000–1,564,000.
Through various secondary studies it can be concluded that Cancer-related Anorexia affects both males and females equally.
Anorexia in cancer has many causes, but the primary cause is often an increase in pro-inflammatory cytokines or an increase in lactate. These two factors then modulate central nervous system neurotransmitter cascades. Additionally, the paper also suggest that anorexia is a major component of cancer cachexia, therefore to develop a effective management strategy for Cancer Anorexia-Cachexia Syndrome (CACS), it is important to fully understand the pathophysiology of anorexia first.
Cancer-related anorexia is a major clinical problem, and adversely influences nutritional status of patients, which may negatively impact patients’ quality of life and increase the burden on healthcare resources.
Anorexia occurs in half of newly diagnosed cancer patients and approximately 26.8-57.9% of patients with advanced cancer.
Cancer Anorexia Causes
The causes of anorexia can be characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis and an increase in protein degradation, or a combination of both. There are numerous causes, which can be conveniently categorized as being due to central or peripheral mechanisms. Peripheral causes can be directly due to tumors causing dysphagia or directly impinging on gastrointestinal function; tumor producing substances that alter food intake, e.g., lactate, tryptophan, or parathormone-related peptide; tumors leading to alterations in nutrients resulting in the condition, e.g., zinc; or tumors producing inflammation leading to cytokine release. On the other hand, central causes of anorexia can be depression, pain, or various alterations in central neurotransmitters.
Cancer Anorexia Diagnosis
Cancer anorexia remains one of the most prevalent and troublesome clinical problems experienced by patients with cancer during and after therapy. In general, the condition’s presence is clinically diagnosed when cancer patients refer to any negative change of their appetite. However, more symptoms such as reduction of appetite, early satiety, changes in taste, changes in odor, depression, dysphagia, painful swallowing, assessment of meal size, assessment of taste and odor are essential to diagnose the condition.
Cancer Anorexia Treatment Market
Several pharmacological and nutritional approaches have been used for the treatment of cancer anorexia. Keeping in mind that both anorexia and metabolic disturbances are involved, the development of different therapeutic strategies has focused on two major factors, namely, improving appetite and neutralizing metabolic disturbances. Current pharmacological agents can be divided into three categories: orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal). Progestagens (megestrol acetate and medroxyprogesterone acetate) are the first-line therapy for cancer anorexia and cachexia. They are highly effective in relieving the symptoms of cancer anorexia. Corticosteroids, mainly dexamethasone, are also widely used to improve appetite in patients with cancer anorexia, however, they are associated with significant side effects. Cannabis such as dronabinol and nabilone have long been recognized to improve appetite, decrease nausea, and enhance food taste. Furthermore, cancer treatment not only decreases the appetite but makes the patient full more quickly when eating. Therefore, apart from these therapeutic agents, patients are recommended dietary changes to effectively cope and manage appetite loss during cancer treatment.
Adlumiz/Edolmizu: Helsinn Healthcare
ART27.13: Artelo Biosciences
NGM120: NGM Biopharmaceuticals
Cancer Anorexia Market Outlook
The treatment of anorexia related to cancer focuses on improving the appetite and neutralizing the metabolic disturbances. Current pharmacological agents can be categorized as orexigenic agents (appetite stimulants), anti-catabolic (anti-metabolic and anti-cytokine) agents, and anabolic agents (primarily hormonal).
Download Free Sample Reoort Now @ https://www.delveinsight.com/sample-request/cancer-anorexia-market
Table of content
1. Key Insights
2. Overview at a Glance
3. Executive Summary
4. SWOT Analysis
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Country-wise Epidemiology
9. Recognized Establishments
10. Unmet Needs
11. Emerging Drugs
12. Seven Major Market Analysis
13. Case Reports
14. KOL Opinion
15. Market Drivers
16. Market Barriers
18. DelveInsight Capabilities
20. About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States